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Abstract
Colorectal cancer (CRC) biopsies underpin accurate diagnosis, but are also relevant for patient stratification
in molecularly-guided clinical trials. The consensus molecular subtypes (CMSs) and colorectal cancer intrinsic
subtypes (CRISs) transcriptional signatures have potential clinical utility for improving prognostic/predictive
patient assignment. However, their ability to provide robust classification, particularly in pretreatment biopsies
from multiple regions or at different time points, remains untested. In this study, we undertook a comprehensive
assessment of the robustness of CRC transcriptional signatures, including CRIS and CMS, using a range of tumour
sampling methodologies currently employed in clinical and translational research. These include analyses using
(i) laser-capture microdissected CRC tissue, (ii) eight publically available rectal cancer biopsy data sets (n= 543),
(iii) serial biopsies (from AXEBeam trial, NCT00828672; n= 10), (iv) multi-regional biopsies from colon tumours
(n= 29 biopsies, n= 7 tumours), and (v) pretreatment biopsies from the phase II rectal cancer trial COPERNCIUS
(NCT01263171; n= 44). Compared to previous results obtained using CRC resection material, we demonstrate
that CMS classification in biopsy tissue is significantly less capable of reliably classifying patient subtype (43%
unknown in biopsy versus 13% unknown in resections, p= 0.0001). In contrast, there was no significant difference
in classification rate between biopsies and resections when using the CRIS classifier. Additionally, we demonstrated
that CRIS provides significantly better spatially- and temporally- robust classification of molecular subtypes in
CRC primary tumour tissue compared to CMS (p= 0.003 and p= 0.02, respectively). These findings have potential
to inform ongoing biopsy-based patient stratification in CRC, enabling robust and stable assignment of patients
into clinically-informative arms of prospective multi-arm, multi-stage clinical trials.
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Recent studies have defined the molecular taxonomy of
colorectal cancer (CRC) by transcriptional, methylation,
and mutational profiling [1–5], culminating in the pub-
lication of four consensus molecular subtypes (CMSs)
[6], two of which reflect pathological well-defined enti-
ties within the tumour microenvironment (TME): CMS1
(high immune-cell infiltration; better prognosis) and
CMS4 (high relative density of stroma, particularly
fibroblasts; poorer prognosis) [7]. A second classifi-
cation, the CRC intrinsic subtypes (CRISs), utilises
epithelial-specific gene expression to potentially provide
prognostic/predictive value [8,9].
Using macrodissected tissue from the central tumour
(CT), invasive front (IF), and lymph node (LN) from
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individual patients (patients, n= 24; samples, n= 72),
we previously demonstrated the potential for discordant
assignment of these patient-of-origin matched samples
when using transcriptional classifiers, as different CMS
classifications were mapped to different regions of the
same tumour, due to stromal-derived intratumoural het-
erogeneity (ITH) [10]. We further demonstrated that
this confounding effect could be resolved by using
epithelial-rich or cancer-cell intrinsic subtypes, such
as CRISs, which demonstrated superior ‘spatial con-
cordance’, with identical CRIS classification achieved
across multiple regions-of-origin in patient-matched
samples [11].
The potential clinical utility of both CMS and CRIS
molecular subtyping has been extensively validated in
CRC resection specimens, and while molecular pro-
filing of surgical resection material is possible in large
retrospective studies [1], the suitability of CRC biopsy
material for prospective molecular stratification has not
been comprehensively assessed. This is increasingly
important, given the number of molecularly-guided
CRC trials that require profiling of pretreatment
biopsies for patient stratification [12].
In this study, we assessed the spatial and tem-
poral stability of clinically-relevant molecular
signatures in diagnostic biopsy material in three
potentially clinically-relevant scenarios. We utilised a
multi-regional (CT and IF) laser capture-microdissected
(LCM) CRC cohort to examine if stromal ITH occurs
with this more precise specimen-preparation method-
ology. Additionally, we assessed subtyping robustness
in a meta-analysis of publicly available rectal cancer
biopsy datasets. We also performed temporal/spatial
assessment of the stability of these classifiers, using
both patient-matched serial biopsies collected over
a 3-week period from the phase II AXEBeam study
[13] and multi-region-of-origin colon biopsies from
the Biopsies of Surgical Specimens (BOSS) study
[14]. Finally, as part of the S:CORT (Stratification in
COloRecTal cancer) research programme [12,15], we
assessed the ability of CRISs and CMSs to classify
histologically-diverse rectal biopsy samples from the
phase II COPERNICUS study.
Materials and methods
Study design
The study design is summarised in the supplemen-
tary material, Figure S1, with details of the patient
cohorts outlined below. Initially, we assessed the
patient-clustering capabilities of CRC gene signatures
in an LCM cohort of invasive front (IF) and central
tumour (CT) regions. We assessed the proportions of
CRIS and CMS molecular subtypes [6,8] in biopsy
material from publically available rectal cancer biopsy
gene expression datasets (in GEO); the details of these
cohorts are outlined in Table 1. We assessed the tem-
poral and spatial stability of CRIS and CMS signatures
Table 1. The eight rectal cancer biopsy gene expression datasets
curated from GEO, their sample size, and the gene expression
profiling platform used
Dataset
Sample
size Platform
GSE56699 58 Illumina WG-DASL
GSE94104 48 Illumina WG-DASL
GSE3493 46 Affymetrix Human Genome U95 Version 2 Array
GSE68204 38 Agilent-014850 Whole Genome Microarray 4×44K
GSE35452 46 Affymetrix Human Genome U133 Plus 2.0 Array
GSE46862 69 Affymetrix Human Gene 1.0 ST Array
GSE45404 42 Affymetrix Human Genome U133 Plus 2.0 Array
GSE87211 196 Agilent-014850 Whole Genome Microarray 4×44K
Total 543
in biopsy samples from AXEBeam and BOSS studies,
respectively [13,14]. Finally, we performed molecular
analysis of biopsies from the COPERNICUS study.
Publically available datasets
All public datasets were downloaded from the gene
expression omnibus (GEO) (https://www.ncbi.nlm.nih
.gov/geo/). Rectal cancer biopsy datasets are detailed
in Table 1. All datasets with sufficient probe-to-gene
annotations and sample size (n> 20) were curated.
When possible, raw unprocessed data were downloaded
and expression profiles underwent standard Robust
Multi-array Average (RMA) normalisation prior to
molecular subtyping. When only post-processed data
were available, we downloaded series matrices to per-
form molecular subtyping. All probes were used and no
variance filtering was performed on any data prior to
molecular subtyping, to ensure the presence of all 273
CMS genes and 565 CRIS genes from the published
classification models.
LCM CRC cohort
GSE65480 is composed of LCM CRC tissue from
20 matched IF and CT regions, profiled using the
Affymetrix Human Gene 1.0 ST Array.
Colon and rectal cancer biopsy datasets
Full details for the arrays employed and sample
numbers analysed for each cohort are detailed in
Table 1, with GEO accession numbers and brief clinical
details for the rectal cancer meta-dataset summarised
below. GSE56699 consists of 58 pretreatment rec-
tal cancer formalin-fixed, paraffin-embedded (FFPE)
biopsy specimens from patients treated with preoper-
ative radiotherapy. GSE94104 consists of 48 locally
advanced rectal cancer (LARC) pretreatment biopsy
specimens from patients treated with long-course
preoperative 5-fluorouracil (5-FU)-based chemora-
diotherapy. GSE3493 contains 46 pretreatment rectal
cancer biopsies from patients treated with preoperative
radiation. GSE68204 comprises 38 pretreatment LARC
biopsy specimens from patients treated with preop-
erative chemoradiotherapy. GSE35452 consists of 46
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018; 245: 19–28
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
Biopsy subtyping in colorectal cancer 21
pretreatment rectal cancer biopsies from patients treated
with 5-FU- and irinotecan-based preoperative chemora-
diotherapy. GSE46862 contains 69 rectal cancer
pretreatment biopsies from patients treated with preop-
erative chemoradiotherapy. GSE45404 consists of 42
pretreatment rectal cancer biopsies from patients treated
with preoperative 5-FU and oxaliplatin-based preoper-
ative chemoradiotherapy. We utilised 196 pretreatment
rectal cancer biopsies from GSE87211, where patients
were treated with a preoperative chemoradiotherapy
regimen consisting of 5-FU alone and FOLFOX.
Colon cancer multi-region-of-origin biopsy cohort
To assess the spatial stability of CMSs and CRISs
in biopsy samples, we utilised transcriptional profiles
from the BOSS study, which were downloaded from
GSE85043. This dataset consists of 29 multi-regional
biopsies from seven patients. Samples were profiled
using the Affymetrix Human Genome U133 Plus 2.0
Array. Importantly, each biopsy had been randomly
taken from the surgical specimen using endoscopic
biopsy forceps to simulate the clinical environment.
Longitudinal serial rectal biopsy cohort
Material from ten matched biopsy samples from
patients recruited to the AXEBeam phase II trial
(NCT00828672; GSE60331) was profiled using the
Affymetrix Primeview array. This trial investigated the
efficacy of bevacizumab/chemo-radiation combination
in rectal cancer. Biopsies were taken before therapy and
3weeks into the first cycle of bevacizumab, but before
chemo-radiation.
Clinical trial cohort
COPERNICUS is a phase II study of neoadju-
vant oxaliplatin-based chemotherapy, followed by
short-course radiotherapy and surgical resection in
patients with rectal cancer. Within S:CORT, we gener-
ated transcriptional profiles using the Affymetrix Almac
Xcel array from the COPERNICUS (NCT01263171)
trial cohort (52 biopsy samples); 50 samples (96.2%)
generated suitable quantities of RNA for analysis, while
44 (84.6%) yielded robust transcriptional profiles.
Gene signatures
We previously evaluated eight CRC gene expression
signatures for variation in their ability to robustly cluster
matched multi-region-of-origin CRC gene expression
profiles [11]. To validate the novel results generated
in the current study using an independent dataset, we
employed the same eight gene expression signatures
as previously published [11]. The 30-gene signature
was developed as a classifier of ‘region-of-origin’ from
a cohort of 24 patient samples using patient-matched
samples from IF, CT, and LN regions (total n= 24).
This cohort is available from the NCBI GEO repository
under accession number GSE95109. [10] The Jorissen
et al signature [16] was developed using transcriptional
profiles from 553 colorectal samples using Affymetrix
Human Genome U133 Plus 2.0 Arrays, to develop a
163-gene ‘metastasis classifier’, which could stratify
stage B and C samples into prognostic subtypes. The
Eschrich et al signature [17] was developed using cDNA
array profiles from 78 colon tumour samples to generate
a 43-gene prognostic signature. The Sadanandam et al
signature [5] (a surrogate for CMS) was developed using
transcriptional profiles from 445 primary CRC resec-
tions using Affymetrix HG-U133Plus2.0 GeneChip
arrays to define 786 subtype-specific signature genes.
The 207 genes associated with classification of the
‘stem-like’ subtype from the original Sadanandam et al
signature were used as our stem-like (CMS4) signature.
The Kennedy et al signature [18] used stage II FFPE
colon cancer tumours on the Almac Colorectal Cancer
DSA platform to define a 634-probeset stage II prog-
nostic signature. The Popovici et al signature [19] was
developed using 668 stage II/III FFPE colon cancer
tissue samples from the PETACC-3 phase III clinical
trial on the Almac Colorectal Cancer DSA platform.
A 64-gene classifier was developed which identi-
fied samples with signalling similar to BRAF-mutant
tumours. The colorectal intrinsic signature (CRIS)
[9] was developed using transcriptional profiles from
515 patient-derived xenograft tumours using Illumina
human-specific 48 k gene chips. A 565-gene classifier
was developed which identified five subtypes based on
their intrinsic epithelial expression profile.
We previously indicated that the 30-gene, stem-like
(CMS4) Jorissen and Eschrich gene signatures contain
genes highly expressed in fibroblasts; the Sadanandam
(CMS) and Kennedy signatures have a more bal-
anced expression across cell types, whilst the Popovici
and CRIS gene signatures contain predominantly
epithelial-specific gene signatures [11].
In addition to the previous eight gene expression
signatures, we assessed the clustering capabilities of
a recently published refined CMS protein expression
classifier [20], which consists of four proteins – CDX2,
FRMD6, HTR2B, and ZEB1, developed using tissue
microarray analysis in combination with MSI geno-
typing, to classify CMS1 (based solely on MSI) and
combined CMS2/3 and CMS4 subtypes. In this pub-
lication, CDX2 is used as a marker for epithelial-like
tumours (CMS2/3), whereas FRMD6, ZEB1, and
HTR2B have higher expression in mesenchymal-like
tumours (CMS4).
Patient classification
To validate the improved ability of CRIS gene sig-
natures to classify by patient-of-origin rather than
region-of-origin, we utilised divisive analysis clus-
tering (DIANA) and normalised Pearson similarity
scoring. This Pearson score was used to define the ratio
between the covariance and the standard deviation of the
multi-region CRC samples, where higher ratios (up to 1)
indicate increased similarity. These two methodologies,
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as previously published, assess variation in clustering
between gene signatures [11]. CMS and CRIS subtypes
were assigned to each gene expression profile using the
previously published methods [6,8,11]. This combined
approach of utilising the published molecular subtyping
CMS and CRIS classifiers, alongside two independent
patient clustering methods (Pearson similarity score and
DIANA), will reduce the possibility that our findings
are confounded by a methodology bias specific to any
particular classification algorithm.
Statistical analysis and graphical representation
Other statistical analyses, including Fisher’s exact and
unpaired t-tests, were performed using GraphPad Prism
6 (GraphPad Software, La Jolla, CA, USA). Plots for
integrative visualisation purposes were generated using
StratomeX tool within Caleydo software version 3.1.5
downloaded from http://caleydo.org/tools/stratomex/.
Assessing tumour content in COPERNICUS samples
A visual assessment of neoplastic cell content, per-
formed only within the macrodissected area of tissue
used for molecular profiling, was made at 4×magnifica-
tion. This value was estimated by a pathologist blinded
to CMS and molecular data.
Results
Patient stratification in epithelial-enriched LCM
CRC specimens
Samples from a cohort of CRC tumour resection tis-
sue samples that had been dissected into CT and IF
regions using LCM were evaluated using a series of
transcriptional profiling approaches (see the Materials
and methods section). Importantly, as this dataset has
been generated using LCM epithelial tissue, it more
closely resembles an epithelial-enriched CRC biopsy
sample, rather than the macrodissected resection tissue
used in our previous studies [10,11].
First, we employed the published CMS classifier
[which uses a random forest (RF) posterior probabil-
ity score] to evaluate each matched CT and IF sam-
ple. Using this method, each tissue sample is assigned
a score for each individual CMS class (i.e. a sample
will have a score for CMS1, CMS2, CMS3, and CMS4)
before a final classification is made. Using these indi-
vidual CMS scores, we created a CMS ratio based on
the change in RF score, from CT and IF regions, for
each patient-matched sample (Figure 1A). We demon-
strated an increase in the relative classification score
for CMS1 and 4 subtypes (the stromal subtypes) in IF
samples compared with patient-matched CT samples in
this LCM cohort. In contrast, the ratios for CMS2 and
3 (the epithelial subtypes) showed a decrease in the IF
regions compared with the CT regions (Figure 1A, left,
GSE65480, n= 20; and supplementary material, Figure
S2A).When comparing the normalised RF classification
scores between combined stromal (CMS1, 4) and epithe-
lial subtypes (CMS2, 3), we observed a statistically sig-
nificant difference between the two groups (Figure 1A,
right, Student’s t-test, p= 0.0001; and supplementary
material, Figure S2B).
We next used a Pearson similarity score in conjunction
with eight CRC-specific classifiers (see the Materials
and methods section and ref 11) to assess the robustness
of classification in these patient-matched samples. This
Pearson similarity analysis indicates variation in tran-
scriptional classification of patient-matched samples
(higher ratios indicate increased similarity), allowing
a focus on the biology underlying the classification
system. Using this method, we highlighted high levels
of concordance of patient-matched samples from differ-
ent regions of the tumour when using gene signatures
that focused on cancer cell intrinsic signalling (CRIS,
Popovici) compared with stromal-dependent signatures
(Figure 1B). Divisive clustering, using the DIANA
methodology, also demonstrated that these signatures
correctly clustered patient-matched samples from dif-
ferent tumour regions (CRIS 95%, Popovici 85%)
compared with stromal-derived signatures (Figure 1C
and supplementary material, Figure S3). Furthermore,
we attempted to use our transcriptional data in combina-
tion with a refined CMS classifier [20], with the caveat
that this refined classifier was originally developed using
four protein expression immunohistochemistry (IHC)
markers to distinguish CMS2/3 from CMS4. Using this
refined IHC CMS classifier, we again observed a poor
patient-matching correlation of our transcriptional data
using DIANA (supplementary material, Figure S4).
Additionally, when re-employing the CMS RF clas-
sifier, alongside the nearest template predictor (NTP)
CRIS classification method, we observed increased
concordance in spatial stability (correct identification
of patient-of-origin) in multi-regional samples when
employing CRIS as opposed to CMS classification
(Figure 1D; CRIS concordance 60% versus CMS 15%,
p= 0.003, Fisher’s exact). We observed that 40% of all
LCM cohort samples profiled could not be confidently
assigned to a CMS group (termed UNK), particularly
in IF samples; only 5% CRIS-UNKs are observed in
the same sample series (Figure 1D; p= 0.0001, Fisher’s
exact).
Molecular subtype assessment in CRC biopsy
meta-dataset
We utilised the online repository GEO by searching
for ‘rectal cancer’ datasets (to 1 March 2017) to curate
a meta-dataset containing 543 treatment-naïve rectal
cancer biopsy gene expression profiles from eight
independent datasets (full details in the Materials and
methods section and Table 1). This meta-dataset con-
sists of gene expression profiles from five different
gene expression platforms, enabling both comparative
assessment between molecular subtyping techniques
and cross-platform correlation (Table 1).
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018; 245: 19–28
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
Biopsy subtyping in colorectal cancer 23
Figure 1. Patient stratification using CRC cell intrinsic signatures. (A) Left: using the CMS classifier, each sample will be assigned an
individual score for CMS1, CMS2, CMS3, and CMS4. Box plots showing the relative CMS ratio for CMS1–4 in patient-matched central
tumour (CT) and invasive front (IF) samples (n= 20). Right: dot plot comparing normalised random forest posterior probability scores for IF
front region of stromal and epithelial CMS subtypes (p= 0.0001, Student’s t-test). (B) Dot plot of normalised Pearson similarity scores for
each gene signature. (C) Table showing clustering concordance by gene signature. (D) Caleydo (Stratomex) integrative visualisation of CRIS
and CMS concordance between matched CT and IF regions.
We classified each individual dataset using the CMS
method [6], resulting in the assignment of a UNK
classification in 43% (n= 252) of patient samples
(Figure 2A, B; range 24–70%). This finding, specifi-
cally in biopsy samples, is considerably higher than the
13% previously observed in CRC resections by Guinney
et al (p= 0.0001, Fisher’s exact) [6]. In contrast, CRIS
classification in the same datasets revealed that only 7%
(n= 37) of patients were UNK (Figure 2A, B; range
2–16%). This observed proportion of CRIS-UNKs
across these biopsy datasets correlates with the 9.2%
CRIS-UNKs identified by Isella et al [8] in CRC
resection specimens (342 UNKs from a total of 3738
samples) (no significant difference, p= 0.07, Fisher’s
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Figure 2. Molecular subtyping of rectal cancer biopsies. (A) Bar charts showing the proportions, average, and total numbers of each CMS
and CRIS group across the eight rectal cancer biopsy datasets. (B) Caleydo (Stratomex) integrative visualisation of CMS and CRIS across
the eight rectal cancer biopsy datasets.
exact). Direct comparison of CMS and CRIS classifica-
tions for each of the 543 rectal cancer biopsies revealed
that 94% of CMS-UNK patients could subsequently
be assigned a CRIS subclass (Figure 1C), indicating
that the transcriptomics data are of sufficient quality for
reliable classification. From these results, in addition
to the previously identified confounding issues with
stromal-derived ITH when using the CMS classifier, we
have demonstrated for the first time CRC patients when
using pretreatment biopsy samples.
Temporal stability of molecular subtypes in serial
biopsy samples
Serial biopsies can provide information on treatment
response and clinically-relevant changes in tumour
biology; therefore, evaluating the temporal stability of
molecular subtypes in repeat CRC biopsies is highly
relevant. We analysed the transcriptional profiles of
ten patient-matched serial biopsy samples (taken both
before and following 3weeks of bevacizumab treatment)
from the AXEBeam phase II trial (NCT00828672;
GSE60331). Again, we confirmed a high number of
UNK samples by CMS analysis (50%, 10/20), with only
30% (3/10) of patients displaying a concordant CMS
classification; lack of classification does not appear to
be due to treatment-induced transcriptional changes,
as six of the ten UNK samples were obtained before
treatment. Conversely, all samples were classified by
CRIS, with 90% (9/10) temporal concordance across
matched serial biopsies taken during this clinical trial
(Figure 3, p= 0.02, Fisher’s exact).
Spatial stability of molecular subtypes in biopsies
of surgical specimens
We have demonstrated that the CRIS classifier provides
a more spatially robust classification than CMS in
multi-region-of-origin LCM CRC cells (Figure 1D).
However, pretreatment biopsies, rather than resection
tissue, are increasingly being used for prospective
molecular stratification. Therefore, we subtyped 29
multi-regional biopsies originating from seven CRC
surgical specimens (between three and five multiple
regions-of-origin samples per patient) from the BOSS
study (GSE85043), using CMS and CRIS classifiers.
We demonstrated that only 1/7 tumours subtyped had
100% concordance in all regions biopsied using the
CMS classifier, whereas 5/7 tumours had 100% concor-
dance using the CRIS classifier (Figure 4). Despite the
small sample size in this cohort, these findings further
confirm our observations from the LCM CRC cohort
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Figure 3. Temporal stability of molecular subtypes in serial biopsies.
Caleydo (Stratomex) integrative visualisation of CRIS and CMS
concordance in serial rectal cancer biopsies from the AXEBeam trial
(n= 10).
(Figure 1D) that CRIS shows greater spatial stability
than CMS in clinically-relevant biopsy material.
Patient stratification in prospective clinical trial
biopsy material
Using transcriptional profiles from COPERNICUS
(n= 44) (see the Materials and methods section),
generated within S:CORT [12], we observed a higher
percentage of patients classified as UNKs when using
CMS compared with CRIS (Figure 5A; 25% versus
5%, p= 0.013, Fisher’s exact). A detailed pathological
review of haematoxylin and eosin (H&E) specimens
was performed to test the ability of histological fea-
ture assessment to predict CMS subtypes, particularly
for the CMS1/CMS4 stromal-dependent subtypes.
In a masked pathological analysis, we observed that
a lower tumour and higher stromal percentage cor-
related with increased CMS1/CMS4 classification
scores (Figure 5B, p = 0.003, Student’s t-test), again
emphasising the histopathological features under-
lying this classification system. This is depicted in
Figure 5C by the representative H&E images of CMS1
(immune-enriched), CMS2/3 (epithelial-enriched), and
CMS4 (fibroblast-enriched) biopsies.
Discussion
Transcriptomic dissection of CRC tumours has
identified two molecular classifiers with potential
clinical relevance. The CMS classifier identifies two
histological subtypes – CMS1 (immune-rich) and
Figure 4. Spatial stability of molecular subtypes in multi-regional
biopsies. Pie charts showing the concordant classification of
multi-regional biopsies from seven surgical specimens in the BOSS
study into CRIS (left) and CMS (right) subtypes.
CMS4 (stromal-rich) – and two epithelial-rich sub-
types – CMS2 (upregulated for WNT and MYC
pathways) and CMS3 (enriched for KRAS mutations
and activation of metabolic pathways). In contrast, the
CRIS classifier identifies five tumour subtypes based on
cancer cell intrinsic biology from within the TME. In
this study, we assessed for the first time the ability of the
CMS and CRIS molecular subtypes to robustly classify
tumour samples, with particular emphasis on prospec-
tive pretreatment biopsy tissue, when confronted with
potential spatial and/or temporal confounders. Initially,
using a cohort of patient-matched LCM invasive front
and central tumour regions from CRC resections, we
demonstrated that the epithelial enrichment achieved
by LCM is not sufficient to overcome the confounding
effect of stromal intratumour heterogeneity. These
results validate our previous findings that CRIS is a
more robust patient stratifier than CMS, while also
indicating that epithelial enrichment using the precise
but time-consuming LCM method cannot eliminate the
potential for stromal-derived ITH to undermine patient
stratification. Our assessment of 543 rectal cancer
biopsies (the largest rectal cancer dataset compiled to
date) also revealed a significantly larger proportion of
unclassified biopsies than has previously been reported
for resection samples when using the CMS classifier.
In contrast, the CRIS classifier assigned the same biop-
sies into proportions consistent with those observed
in resection material. This observation indicates that
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Figure 5. Molecular subtyping and tumour content in biopsy material from the phase II COPERNICUS clinical trial. (A) Bar charts showing
the percentage of patients from each subtype, CMS (left) and CRIS (right), in the COPERNICUS cohort. (B) Dot plots comparing the tumour
percentage between stromal subtypes (CMS1 and 4) and epithelial subtypes (CMS2 and 3) (Student’s t-test, p= 0.003). (C) Representative
H&E images of CMS1 (left), CMS2/3 (middle), and CMS4 (right) biopsies (×10 original magnification).
while CMS classification provides important prognostic
information in CRC resection samples, it may not be
suited to classification in FFPE biopsy material.
We also demonstrated increased temporal con-
cordance with the CRIS classifier when assessing
longitudinal rectal cancer biopsies from patients
recruited to the phase II AXEBeam clinical trial. As
temporal stability of molecular subtypes could be con-
founded by therapy-related gene expression alteration
[21] (although this is not indicated by our current anal-
ysis), we believe that this observation warrants further
investigation in treatment-naïve samples or indeed
with standard-of-care chemotherapy samples, in order
to fully understand the implications of this evolving
biology. In line with our analysis in the LCM CRC
cohort and the rectal cancer meta-dataset, we again high-
lighted the superior spatial stability of CRIS compared
with CMS in a multiple region-of-origin cohort using
colon cancer biopsies (BOSS study). Finally, we coupled
histopathological assessment and molecular subtyping
of pretreatment rectal cancer biopsies from the phase
II COPERNICUS clinical trial, where we observed low
tumour percentage (and high stromal content) to be cor-
related with the stromal CMS subtypes (CMS1 and 4).
CRC biopsies are currently used for both cancer diag-
nosis and patient stratification, employing small panels
of clinically important biomarkers, such as RAS muta-
tional status, although despite providing useful clini-
cal information, they currently lack both prognostic and
positive predictive value. Increasingly, biopsy samples
are being considered for molecular stratification using
high-throughput transcriptional profiling, particularly in
the adjuvant/neoadjuvant clinical trial setting, to aid
in patient assignment into prognostic and/or predic-
tive subgroups. The prognostic and predictive potential
of CMS (and CRIS) molecular subtypes has, to date,
been investigated using large retrospective collections
of resected CRC tissue [6,8]; our present study high-
lights the need for rigorous testing and refinement of
CRC classifiers using prospective biopsy tissue, thus
facilitating their employment as clinically-useful tools
in patient stratification. Molecular analysis of patient 6
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Figure 6. Proposed model of stromal heterogeneity confounding
CMS subtyping in colorectal cancer biopsies depicting the molecu-
lar classification for Patient 6 from the BOSS analysis in Figure 4.
from the BOSS study (see Figure 4) illustrates the point;
all four biopsy samples from across the surgical speci-
men were assigned CRIS-A classification (100% con-
cordance), whereas multiple CMS classifications were
assigned from the same four biopsy samples, includ-
ing CMS3 (2/4 biopsies), CMS1 (1/4 biopsies), and
CMS4 (1/4 biopsies). Given the current prognostic algo-
rithm associated with CMS classification, these results
would be of little utility in patient stratification, as they
would reveal a patient who has a tumour with either
a good prognosis (CMS1), an intermediate prognosis
(CMS3) or a poor prognosis (CMS4), depending on the
region of origin of the biopsy sample. The 100% concor-
dance observed with CRIS classification, independent
of region of origin, suggests that CRIS classification is
the methodology of choice when using a single biopsy
approach to patient stratification. Ubink et al indicate
via their analysis that setting a threshold for CMS4
detection across multiple biopsies may help to ensure a
more robust classification [14]. However, taking multi-
ple biopsies across the IF and CT regions of a tumour in
the clinical setting may not always be feasible, nor is it
part of current standard pathology practice. In contrast to
the robust and reproducible nature of CMS classification
in large resection tissue samples [6], our data reveal mul-
tiple conflicting subtype assignments, depending on the
tumoural region sampled during tissue collection, with
stromal-based classifiers like CMS specifically when
using biopsy samples. We propose that using the CRIS
classifier transcends this stromal heterogeneity, resulting
in a robust patient classification methodology regard-
less of the proportions of TME-derived material even in
biopsy tissue (Figure 6).
Biomarker-informed clinical trials such as
FOxTROT (ISRCTN 87163246) and FOCUS4
(ISRCTN90061546) have involved the application
of multiple molecular tests on biopsy material, which
may be limited in quantity (and potentially quality), fol-
lowing diagnostic assessment. While these studies have
employed mutational status for patient stratification,
evaluation of transcriptional-based signatures in collab-
orative programmes such as S:CORT aims to provide
a clinical rationale for such stratification in clinical
practice. There is no doubt as to the potential clinical
importance of the TME and CMS classification system,
with numerous studies highlighting its prognostic value.
However, given the nature of stromal ITH and the
current lack of a standardised method for the collection
of biopsy material, even within ongoing clinical trials,
this method can easily be confounded by sampling bias.
The implementation of a standardised biopsy collection
method may remove this confounding issue, but until
such a reproducible biopsy protocol is developed, our
data support the use of CRIS stratification as the molec-
ular pathology methodology of choice underpinning
reproducible prospective patient stratification from
current routine biopsy tissue.
In addition to a robust subtype assignment and clear
prognostic value, the clinical relevance of defining
CRIS lies in its potential predictive value, which gives
insights into the biology underlying the epithelial
component of the tumour, which may in turn guide an
informed (targeted) therapy approach. We have previ-
ously shown that CRIS-C patient-derived xenografts
(PDX) respond to EGFR inhibition (cetuximab) [8],
which was further validated using tumour profiles from
a phase II metastatic CRC study [22]. Preliminary
results from FOxTROT have confirmed the feasibility
of stratifying colon cancer patients, using pretreatment
biopsies, for targeted (panitumumab) and/or cytotoxic
chemotherapy treatment in the neoadjuvant setting. The
data presented here support the use of CRIS profiling
of pretreatment biopsy material to inform precision
oncology stratification based on the specific biology
of the disease, determined using diagnostic endoscopic
tissue. The ‘window-of-opportunity’ study design, as
used in FOxTROT, urgently requires robust biomarkers
linked to distinct therapeutic choices in order to select
patients for more personalised treatments. Based on our
findings, classification of samples based on cancer-cell
intrinsic properties, such as CRIS, is necessary to guide
testing of novel treatment interventions in the first-line
preoperative setting, where they have the greatest
chance of achieving therapeutic response(s).
In conclusion, we highlight the robust nature of the
CRIS transcriptional classifier in diagnostic endoscopic
biopsy material, which is the relevant entry point to
ongoing and forthcoming CRC clinical trials. The limi-
tations of CMS identified previously by our group are
still evident when using LCM processing of samples,
suggesting that this time-consuming method does not
eliminate the potential for ITH to confound patient clas-
sification, as previously identified in macrodissected
samples. Given the limited control over the spatial
region-of-origin of biopsy tissue available for analy-
sis, our current data support patient stratification using
CRIS transcriptional subtypes, which minimise poten-
tially confounding ITH. This work provides a strong
rationale to investigate the prognostic/predictive value of
CRIS subtypes in biopsy-led and statistically-powered
prospective CRC trials.
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